-+ 0.00%
-+ 0.00%
-+ 0.00%

MAREA THERAPEUTICS, A SUBSIDIARY OF LISATA THERAPEUTICS, ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 CLINICAL TRIAL OF MAR002, A POTENTIAL BEST-IN-DISEASE INVESTIGATIONAL THERAPY FOR THE TREATMENT OF ACROMEGALY

Reuters·10/05/2026 12:00:05

Please log in to view news